Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC Blinatumomab + Low Intensity Chemotherapy in Older/Unfit Patients With Newly Diagnosed B-ALL
NCT07153796Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2026
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2026; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07153796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153796.